Adenosine A2A Receptor Agonists for Airway Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceuticals lack effective compounds that can specifically target and activate the adenosine A2A receptor to treat inflammatory and allergic conditions, particularly in obstructive airways diseases and inflammatory disorders.
Innovation Solution
Development of organic compounds of formula (I) that act as A2A receptor agonists, specifically activating the adenosine A2A receptor, which are synthesized through a process involving reacting compounds of formula (II) and (III) to produce compounds suitable for pharmaceutical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceuticals are used, then general anti-inflammatory effects are achieved, but specific A2A receptor activation is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying molecular parameters of adenosine derivatives (substituents at positions 2, 6, and N9 of the purine ring) to optimize A2A receptor binding affinity and selectivity, achieving Ki values below 1.0 µM with high specificity for the A2A subtype among adenosine receptors
2Adaptability or versatility
If adenosine A2A receptor agonists are developed, then treatment of inflammatory and allergic conditions is improved, but lack of specific compounds previously limited therapeutic options
Solution Approach 1:
The patent applies segmentation by dividing the adenosine receptor family into distinct subtypes (A1, A2A, A2B, A3) and developing compounds with selective affinity for the A2A subtype through specific molecular structural features, enabling targeted therapy for inflammatory and allergic conditions
Solution Approach 2:
The patent employs composite molecular structures combining the adenosine core (purine ring) with various substituent groups (halogens, alkyl chains, heterocyclic rings) to create a series of A2A selective agonists with optimized pharmacological properties for different therapeutic applications
Data Source
AI summary
A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.